Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA) discloses an equity award to insider David Young, the company’s President, R&D and a director.
- Transaction date: 07/24/2025
- Security: 1,813,133 restricted stock units (RSUs) granted at $0 exercise price under the 2019 Omnibus Incentive Plan.
- Contingency: 1,790,833 of the RSUs require stockholder approval of the revised Omnibus Plan.
- Vesting schedule: One-third vests 01/01/2026; the balance vests monthly in equal installments through 01/01/2028 (one-thirty-sixth per month).
- Post-grant holdings: Young now beneficially owns 1,821,016 derivative securities.
- Ownership type: Direct.
No non-derivative transactions were reported and no sale or disposition occurred. The filing only records the RSU grant and the associated vesting and approval conditions.
Processa Pharmaceuticals (PCSA) – Form 4 Insider Filing
On 24 Jul 2025, Chief Executive Officer & Director George K. Ng received 1,822,471 Restricted Stock Units (RSUs) under the 2019 Omnibus Incentive Plan at a $0 exercise price. Each RSU converts into one common share as follows: one-third vests on 1 Jan 2026 and the remainder vests monthly through 1 Jan 2028. Footnote 1 states that 1,859,318 of the underlying shares are contingent on stockholder approval of a revised plan.
After the grant, Ng beneficially owns 1,922,471 derivative securities linked to PCSA common stock, all held directly. No open-market purchases or sales were reported; the transaction reflects an equity-based compensation award that could add up to roughly 1.8 million new shares to the float once vested and, where applicable, approved.